pRNFL as a marker of disability worsening in the medium/long term in patients with MS
Citation Manager Formats
Make Comment
See Comments

MS is an inflammatory and neurodegenerative disease of the CNS (including the retina) that leads to progressive neurologic disability. Disability correlates with the degree of axonal pathology in the disease.1,2 The clinical course of MS is unpredictable, making the search for biomarkers associated with enhanced risk of disease progression a major unmet need. Spectral domain optical coherence tomography (SD-OCT) is a potential predictor of disability worsening up to 5 years of follow-up after a single evaluation of the peripapillary retinal nerve fiber layer (pRNFL).3 Time domain OCT (TD-OCT) is an older technology, characterized by lower axial resolution and slower acquisition speed (400 axial scans per second) resulting in lower resolution images and more frequent motion artifacts compared with SD-OCT.4 TD-OCT was used over 10 years ago to assess retinal neurodegeneration in patients with MS but only now has enough time passed to assess its actual predictive potential for clinical progression.
To investigate the capacity of TD-OCT measures to predict disability worsening in patients with MS, we performed a retrospective evaluation of 305 patients with MS (228 relapsing-remitting, 29 secondary progressive, 32 clinically isolated syndrome, 10 primary progressive MS according to 2005 McDonald criteria,5 and 6 with MS but unclear disease course) who had undergone Stratus TD-OCT (Carl Zeiss Meditec AG, Jena, Germany) from January 2006 to December 2008, collecting the values of the pRNFL and macular volume (MV). The Committee on Human Research at UCSF approved the study. All participants provided written informed consent. The baseline cohort characteristics are presented in the table. All patients had at least 1 measurement of the Expanded Disability Status Scale (EDSS) during the subsequent follow-up period. In our analyses, we used the most recent available EDSS. The median follow-up duration from the time of OCT to the most recent EDSS evaluation was 7.9 years (interquartile range 6.4–8.9 years, range 0.04–9.5 years); 91% of the cohort had >5 years of follow-up. The association between the baseline pRNFL and the subsequent EDSS was investigated using multivariable linear regression, adjusted for age and sex, taking into account the correlation of pRNFL thickness in the patient's 2 eyes (figure). For each 1-μm decrease in the pRNFL, there was a 0.024 increase in EDSS (95% CI: 0.011–0.037; p < 0.001). In a sensitivity analysis, the results were similar (0.022 increase in the EDSS, 95% CI 0.035–0.01, p = 0.001) when analyzing only patients with >5 years of follow-up. A model adjusted for the presence of previous episodes of optic neuritis yielded similar results (a 1-μm decrease in the RNFL was associated with a 0.024 increase in the EDSS; p < 0.001). There was no association with MV. The lack of consistent association of MV with disability worsening has previously been reported3 and may relate to the lack of segmentation from whole macular thickness where some layers increase volume and others lose volume during the course of disease. In addition, TD-OCT had poorer reproducibility for volume scans because of the low speed of image acquisition. These results show that TD-OCT and a single evaluation of pRNFL atrophy is useful in predicting disability up to 6–9 years later in MS—significantly longer than has been previously reported. A limitation of the study is the absence of the baseline EDSS in the entire cohort, which limited our ability to consider its influence as a confounder in the estimate of association between the baseline RNFL and subsequent EDSS. Recent meta-analyses show that the mean RNFL loss in a population of patients with optic neuritis is similar between TD-OCT and SD-OCT.6,7 However, despite the similarity in means at an individual level, SD-OCT is known to be more accurate. Stratus TD-OCT is no longer used in MS research because of the availability of more sophisticated OCT machines being able to quantify retinal measures with a much lower level of noise.8 Nevertheless, despite the effect on SDs, this noise does not affect the mean, and data from earlier iterations of the technology can be useful to indicate the association between retinal thinning and future disability.
Demographic and baseline characteristics and the follow-up data of the study population (number of patients = 305)
RNFL = retinal nerve fiber layer.
Author contributions
C. Cordano: study concept and design, interpretation of data, and composition of the manuscript. B. Nourbakhsh: analysis and interpretation of data. M. Devereux and V. Damotte: acquisition of data and composition of the manuscript. D. Bennett: acquisition of data and supervision of the manuscript. S.L. Hauser and B.A.C. Cree: study supervision and composition of the manuscript. J.M. Gelfand: analysis and interpretation of data and composition of the manuscript. A.J. Green: study concept and design, analysis and interpretation of data, and composition of the manuscript.
Study funding
No targeted funding reported.
Disclosure
C. Cordano received research support from FISM and served as a consultant for Inception 5. B. Nourbakhsh received research support from Biogen, American Brain Foundation, National Multiple Sclerosis Society, and Patient-Centered Outcome Research Institute. M. Devereux reports no disclosures. V. Damotte received travel funding from ECTRIMS and ARSEP Foundation. D. Bennett reports no disclosures. S.L. Hauser served on the scientific advisory boards of Symbiotix, Annexon, Bionure, Molecular Stethoscope, Alector, and Neurona; received travel funding and speaker honoraria from F. Hoffmann La Roche; receives publishing royalties from McGraw-Hill Education; received writing support from F. Hoffmann La Roche; and received research support from the NIH, NMSS, and Conrad N. Hilton Foundation. B.A.C. Cree served on the scientific advisory board of Akili and consulted for AbbVie, Biogen, EMD Serono, GeNeuro, Novartis, and Sanofi Genzyme. J.M. Gelfand served on the DSMB for an NIA-funded study; is on the editorial board of Neurology: Neuroimmunology & Neuroinflammation; received publishing royalties from DynaMed Plus; consulted for Biogen; received research support from MedDay and research support (to UCSF) from Genentech; is PI of an institutional clinician training award from the NMSS; received compensation for medical-legal consulting; his spouse is an associate editor of JAMA Neurology; received honoraria from UpToDate; and consulted for Zosano, Eli Lilly, Biohaven, and eNeura. A.J. Green served on the scientific advisory boards of MedImmune, Novartis, Inception 5 Sciences, Pipeline, and Bionure; served as an associate editor of JAMA Neurology and editorial board member of Neurology; holds a patent for remyelination molecules and pathways; received research support from Novartis, Inception Sciences, NINDS, NIA, NIH, NMSS, Sherak Foundation, and Hilton Foundation; holds stock or stock options in Inception 5, Pipeline, and Bionure; and served as an expert witness in Mylan Pharmaceuticals v Teva Pharmaceuticals. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NN.
Footnotes
Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NN.
The Article Processing Charge was funded by the authors.
- Received July 19, 2018.
- Accepted in final form November 8, 2018.
- Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
References
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
No evidence of disease activity is associated with reduced rate of axonal retinal atrophy in MSMarco Pisa, Simone Guerrieri, Giovanni Di Maggio et al.Neurology, November 15, 2017 -
Article
Association of Spectral-Domain OCT With Long-term Disability Worsening in Multiple SclerosisJeffrey Lambe, Kathryn C. Fitzgerald, Olwen C. Murphy et al.Neurology, March 02, 2021 -
Drugs and Devices
The application of optical coherence tomography in neurologic diseasesRamiro S. Maldonado, Pradeep Mettu, Mays El-Dairi et al.Neurology: Clinical Practice, September 17, 2015 -
Article
Fingolimod treatment in multiple sclerosis leads to increased macular volumeRachel Nolan, Jeffrey M. Gelfand, Ari J. Green et al.Neurology, December 05, 2012